This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This transformation will particularly benefit organizations that can effectively combine AI expertise with traditional pharmaceutical knowledge, creating new competitive advantages in drugdevelopment efficiency, cost management, and market responsiveness.
The new company aims to leverage its extensive data sets and technology to provide innovative solutions across various healthcare sectors, including lifesciences, provider, imaging, health plan, employer, and government health and human services. Subscribe Today! Subscribe Today!
In our interview, Gil emphasizes the critical role of AI in expediting the discovery of new drugs, citing the lengthy and costly nature of traditional drugdevelopment processes. However, with AI-driven approaches, Aion Labs is paving the way for a paradigm shift in drug discovery.
With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the lifesciences and healthcare sector. However, they are vital to the drugdevelopment and approval process and critical in enabling access to innovative medicines.
The development and manufacturing process for these important new drugs is very different from traditional medicines. This article focuses on the technology that ensures quality in the process, and is based on a conversation with Graziella Piras, PhD, LifeScience Business Development Director at 908 Devices.
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drugdevelopment, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
We are particularly excited about the ability of these tools to drive more efficient and faster drugdevelopment processes in the biopharma industry.” “The Flywheel helps organizations turn complex imaging data into analysis-ready datasets for accelerated research and AI development.
Given the improvements in costs, trial sponsors can now take advantage of these exchanges at scale and leverage the data for both pre-screening and health economic analysis. As DCTs and virtual site acceptance accelerates, a knock-on effect will be that more of these trials will include HEOR analysis.
Cornerstone is developing highly intelligent, automated software to accurately and efficiently clean and prepare data in a fraction of the time of traditional methods. Its software can significantly accelerate data analysis and healthcare research. The company also announced a $5 million seed round led by Healthy Ventures.
Jesse Cugliotta, Global Industry GTM Lead, Healthcare & LifeSciences at Snowflake. Patient insight management will be a key strategic pillar: Lifescience organizations are more confident in the business value of insights management and are increasingly willing to commit the necessary technological resources to support this need.
Down rounds, where a private company raises money at a price lower than its previous valuation, accounted for 9% of venture financing in the third quarter, according to an analysis by law firm Fenwick & West, while up rounds accounted for 78%. But key facets of its business didn’t develop as planned, say people familiar with the company.
Corporate Development for Healthcare Technology companies in EMEA Healthcare Technology Thought Leadership from Nelson Advisors – Market Insights, Analysis & Predictions. Visit [link] HealthTech Corporate Development - Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors. Subscribe Today!
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content